Sharemaestro Newsreel

Chase Investment Counsel Corp Takes $1.82 Million Position in Harmony Biosciences Holdings, Inc. $HRMY

Chase Investment Counsel Corp has acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), purchasing 50,000 shares valued at approximately $1.82 million, representing a 0.09% stake. Harmony Biosciences reported strong quarterly earnings of $1.28 per share, exceeding estimates, with revenue increasing by 30.3% …

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs

Silence Therapeutics plc announced the closing of its upsized public offering, which included the full exercise of the underwriters' option to purchase additional American Depositary Shares (ADSs). The offering, consisting of 14,907,407 ADSs at $13.50 per ADS, generated gross proceeds of approximately $201.3 million. …

BeyondSpring Inc. (BYSI) Reports Q2 Loss of $0.02

BeyondSpring Inc. (NASDAQ: BYSI) announced its Q2 earnings, reporting a loss per share of $0.02. This figure compares to an EPS of $0.00 reported in the same quarter last year. Investors can find additional earnings history and related data on BeyondSpring Inc. through the …

Wave Life Sciences Ltd. SEC Filing (Aug 17, 2026)

This article reports on an SEC filing by Wave Life Sciences Ltd. (WVE) on August 17, 2026, which is a Notice of Effectiveness with an effective date of August 14, 2026. The filing has a neutral impact and sentiment according to AI analysis. The …

Horizon Investment Services LLC Buys Shares of 28,793 Halozyme Therapeutics, Inc. $HALO

Horizon Investment Services LLC has acquired 28,793 shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) worth approximately $2.25 million in the second quarter. This move is part of broader institutional investment, with collective ownership by institutional investors and hedge funds standing at 97.79%. Halozyme Therapeutics recently …

Syncona Portfolio Ltd Buys Shares of 16,640,720 Autolus Therapeutics PLC Sponsored ADR $AUTL

Syncona Portfolio Ltd has acquired a significant new stake of 16,640,720 shares in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL), representing 6.25% of the company and approximately 100% of Syncona's portfolio. Institutional investors now own 72.83% of AUTL, which has a "Moderate Buy" consensus rating …

[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer)

ALTERITY THERAPEUTICS LTD filed a Form 6-K, a current report for foreign private issuers, with the SEC. The filing, dated August 17, 2026, includes an exhibit related to disclosure under Takeovers Panel GN 20. This report is incorporated by reference into several of the …

44,466 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by GSA Capital Partners LLP

GSA Capital Partners LLP recently acquired 44,466 shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) valued at approximately $1.81 million. Other institutional investors also increased their holdings, while company insiders sold shares primarily to cover tax obligations related to vested equity awards, maintaining significant ownership. Analysts …

OmniAb partners with Eli Lilly on ion channel program By Investing.com

OmniAb, Inc. announced a global collaboration and license agreement with Eli Lilly and Company for an ion channel drug discovery program. The agreement includes an upfront payment to OmniAb, eligibility for up to $370 million in milestone payments, and tiered royalties on global net …

Does BioMarin’s Raised 2026 Outlook and ESOP Shelf Offering Reshape the Bull Case for BMRN?

Earlier this month, BioMarin Pharmaceutical reported second-quarter 2026 results showing revenue of US$989.71 million and updated earnings guidance for the second half and full year, including a slight increase in its 2026 revenue outlook to US$3.88 billion–US$3.93 billion. Alongside these results, BioMarin filed a …

Going-concern warning at XORTX (XRTX) as losses mount

XORTX Therapeutics Inc. (XRTX) reported an interim net loss of $2.50 million for the six months ended June 30, 2026, widening from $1.42 million a year prior. The company's management has issued a going-concern warning, citing ongoing losses and a limited cash balance of …

OmniAb Expects Year-End Cash of Up to $53M—What Drove the Change?

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

EMERYVILLE, Calif., August 17, 2026--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The …

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

Outlook Therapeutics (OTLK) used its fiscal third-quarter 2026 earnings call to outline the U.S. launch plan for LYTENAVA, an FDA-approved treatment for wet AMD, targeting a launch before year-end 2026. The company set a base-case objective of over $500 million in annual U.S. sales …

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Corbus Pharmaceuticals Holdings, Inc. announced inducement equity awards granted to Leonardo Nicacio, the new Chief Medical Officer, under Nasdaq Listing Rule 5635(c)(4). These grants include a nonstatutory stock option to purchase 191,676 shares and restricted stock units for 58,333 shares, both vesting over four …

GSA Capital Partners LLP Makes New $1.97 Million Investment in Tenaya Therapeutics, Inc. $TNYA

GSA Capital Partners LLP has made a new investment of approximately $1.97 million in Tenaya Therapeutics (NASDAQ:TNYA), acquiring 2.67 million shares, which represents a 1.23% stake in the company. Institutional investors now own 90.54% of Tenaya Therapeutics, despite the company missing its Q2 revenue …

GSA Capital Partners LLP Buys New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL

GSA Capital Partners LLP has acquired a new stake of 374,260 shares in Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL), valued at approximately $1.815 million. This purchase makes GSA Capital Partners LLP the owner of 0.53% of Zentalis Pharmaceuticals. Other institutional investors also made significant moves in …

GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD

GSA Capital Partners LLP has initiated a new investment in ACADIA Pharmaceuticals Inc., purchasing 70,484 shares valued at approximately $1.78 million during the second quarter. This move is part of a broader trend, with several other hedge funds also adjusting their positions in the …

Venture investor’s big move: Latigo Biotherapeutics (ALMS) lands new 14.5% holder

Venture investor James B. Tananbaum, through Foresite Capital funds, has reported beneficial ownership of 9,181,328 shares, or 14.5%, of Latigo Biotherapeutics (ALMS) common stock. This significant stake was accumulated through various venture investments, including preferred stock purchases between 2022 and 2025, a convertible promissory …

Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands

Palvella Therapeutics is targeting a 2027 approval for its lead candidate, QTORIN rapamycin, for microcystic lymphatic malformations (mLM), with a New Drug Application submission planned by year-end. The company is preparing for self-commercialization in the U.S. and estimates an annual price of $100,000-$200,000 per …

GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX

GSA Capital Partners LLP has acquired a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), purchasing 62,775 shares valued at approximately $1.37 million during the second quarter. This move comes as several other institutional investors also increased their holdings in the company. Despite missing revenue …

Corcept Therapeutics (CORT) Stock Analysis: Unveiling an 18% Potential Upside amid Robust Revenue Growth

Exelixis, Inc. (EXEL) Stock Analysis: Evaluating the 3.31% Upside with Strong Revenue Growth

Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth

Genmab A/S (GMAB) Stock Analysis: A 21.59% Upside Potential Amid Robust Revenue Growth

LeonaBio Inc (LONA) Q2 Results Highlight Challenges for Valuatio

Insmed Incorporated (INSM) Stock Analysis: 61.67% Potential Upside Amidst Robust Revenue Growth

Incyte Corporation (INCY) Stock Analysis: Exploring 37.7% Revenue Growth and a Promising Pipeline

Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?

Cogent Biosciences (COGT) recently reported wider net losses for Q2 and H1 2026, with a net loss of US$96.41 million for the quarter and US$193.76 million for the half-year. Despite a strong 213.21% total shareholder return over the past year, its 90-day share price …

Citizens reiterates Allogene stock rating on trial progress

Citizens reiterated a Market Outperform rating on Allogene Therapeutics Inc. (NASDAQ:ALLO), maintaining a $6.00 price target. The firm's analysis is based on discounted EPS and revenue multiples, with the company's ALPHA3 trial on track for an interim readout in mid-2027. Allogene reported strong second-quarter …

Chase Investment Counsel Corp Buys New Stake in Halozyme Therapeutics, Inc. $HALO

Chase Investment Counsel Corp has acquired a new stake of 26,000 shares in Halozyme Therapeutics, valued at approximately $2.0 million. This comes as institutional investors now collectively own 97.79% of the company. Despite insider selling activity, analyst sentiment remains largely positive with a "Moderate …

Moderna CEO Stephane Bancel sells $28.7m in shares By Investing.com

Moderna CEO Stephane Bancel sold 499,246 shares of company stock for approximately $28.7 million in early August 2026, while simultaneously acquiring 751,715 shares through stock option exercises worth $14.4 million. These transactions were conducted under a Rule 10b5-1 trading plan. The sales primarily covered …

70,000 Shares in Innoviva, Inc. $INVA Purchased by Chase Investment Counsel Corp

Chase Investment Counsel Corp has acquired 70,000 shares of Innoviva, Inc. (NASDAQ:INVA) for approximately $1.59 million, representing a new stake of about 0.09% in the company. Institutional ownership in Innoviva remains high at 99.12%, with firms like Vanguard Group and Arrowstreet Capital also increasing …

Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup

Abeona Therapeutics (ABEO) Q2 Revenue Misses Estimates; Market Pricing Reflects Growth Uncertainty

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of "Moderate Buy" by Brokerages